Examinando por Autor "Weiser, Roberto"

Mostrando 1 - 2 de 2

Multiple sclerosis in Central America and Caribbean countries: frequency and clinical characterization of an emergent disease
(Los autores, 2024) Gracia, Fernando; Ramírez Navarro, Deyanira A; Ramírez Sánchez, Nicia E; Weiser, Roberto; Parajeles-Vindas, Alexander; Portillo Rivera, Ligia I; López Torres, Ericka; García Valle, Luis A; Sanabria-Castro, Alfredo; Abdón López, César; Araujo, Pahola; Ayerdis Zamora, Maria J; Balmaceda-Meza, Andrea; Benzadon Cohen, Aron; Candelario Cueto, Awilda; Castillo, Diego; Castro-Escobar, Romy; Corea Urbina, Karla Z; Peña Rivas, Anyeri de; Duarte Sotelo, Octavio; Enamorado Claros, Temís; Giroud Benítez, José L; Gracia, Karla; Larreategui, Mario; Martínez Cerrato, Jorge A; Medina Báez, Josmarlin P; Menjivar Samayoa, Carlos E; Miranda-Loria, Gustavo; Monterrey-Alvarez, Priscilla; Morales Arguello, Lilliam A; Ortiz, Michelle; Pérez Baldioceda, Carlos D; Pinilla Aguilar, Lizeth; Rodríguez Salinas, Luis C; Rodríguez-Moreno, Virginia; Rojas-Chaves, Sebastián; Román-Garita, Norbel; Santos Pujols, Biany; Valderrama, Carlos; Van Sijtveld, Ivonne; Zabala Angeles, Indhira; Rivera, Victor M; Armien, Blas
Background: Multiple Sclerosis (MS) is a common neurological disease among white populations of European origin. Frequencies among Latin Americans continue to be studied, however, epidemiologic, and clinical characterization studies lack from Central American and Caribbean countries. Ethnicity in these countries is uniformly similar with a prevalent Mestizo population. Methods and results: Data from January 2014 to December 2019 from Guatemala, El Salvador, Honduras, Nicaragua, Costa Rica, Panama, Dominican Republic, and Aruba on demographic, clinical, MRI and phenotypic traits were determined in coordinated studies: ENHANCE, a population-based, retrospective, observational study on incidence and clinical characteristics, and from the subgroup with MS national registries (Aruba, Dominican Republic, Honduras, and Panama), data on prevalence, phenotypes and demographics. Expanded Disability Status Scale (EDSS), and therapeutic schemes were included. ENHANCE data from 758 patients disclosed 79.8% of Mestizo ethnicity; 72.4% female; median age at onset 31.0 years and 33.2 at diagnosis. The highest incidence rate was from Aruba, 2.3–3.5 × 100,000 inhabitants, and the lowest, 0.07–0.15 × 100,000, from Honduras. Crude prevalence rates per 100,000 inhabitants fluctuated from 27.3 (Aruba) to 1.0 (Honduras). Relapsing MS accounted for 87.4% of cases; EDSS <3.0 determined in 66.6% (mean disease duration: 9.1 years, SD ± 5.0); CSF oligoclonal bands 85.7%, and 87% of subjects hydroxyvitamin D deficient. Common initial therapies were interferon and fingolimod. Switching from interferon to fingolimod was the most common escalation step. The COVID-19 pandemic affected follow-up aspects of these studies. Conclusion: This is the first study providing data on frequencies and clinical characteristics from 8 countries from the Central American and Caribbean region, addressing MS as an emergent epidemiologic disorder. More studies from these areas are encouraged
Neuromyelitis Optica Spectrum Disorder in Central America and the Caribbean: A Multinational Clinical Characterization Study
(Los autores, 2022) Gracia, Fernando; Ramírez, Deyanira; Parajeles-Vindas, Alexander; Díaz, Alejandro; Díaz de la Fé, Amado; Ramírez Sánchez, Nicia Eunice; Castro Escobar, Romy; García Valle, Luis Alberto; Weiser, Roberto; Santos, Biany; Candelario, Awilda; Benzadon, Aron; Araujo, Pahola; Valderrama, Carlos; Larreategui, Mario; Carrillo, Gabriela; Gracia, Karla; Vázquez-Céspedes. Johana; Monterrey-Alvarez, Priscilla; Carazo-Céspedes, Kenneth; Sanabria-Castro, Alfredo; Miranda-Loria, Gustavo; Balmaceda-Meza, Andrea; Portillo Rivera, Ligia Ibeth; Olivera Leal, Irma; Rodriguez Salinas, Luis Cesar; Thompson, Arnold; López Torres, Ericka; Pereira, Daniel Enrique; Zepeda, Carolina; Abdón López, César; Cornejo Valse, Ernesto Arturo; Corea Urbina, Karla Zinica; Urrutia, Marco Antonio; Van Sijtveld, Ivonne; Armien, Blas; Rivera, Victor M
Here, a study of NMOSD in Central America and the Caribbean with a multinational collaborative, multicentric and descriptive approach involving 25 institutions from 9 countries is presented. Demographics, clinical manifestations, expanded disability scale status (EDSS), brain and spinal cord MRI, serological anti-AQP4-IgG and anti-MOG-IgG antibodies, and cerebrospinal fluid (CSF) oligoclonal bands were included. A central serological repository utilized the cell-based assay. The specimens outside of this network employed diverse methodologies. Data were collected at the Gorgas Commemorative Institute of Health Studies (ICGES), Panama, and included 186 subjects, of which 84% were females (sex ratio of 5.6:1). Mestizos constituted 72% of the study group. The median age was 42.5 years (IQR: 32.0–52.0). Associated autoimmune diseases (8.1%) were myasthenia gravis, Sjögren’s syndrome and systemic lupus erythematosus. The most common manifestation was optic neuritis-transverse myelitis (42.5%). A relapsing course was described in 72.3% of cases. EDSS scores of 0–3.5 were reported in 57.2% of cases and higher than 7.0 in 14.5%. Positive anti-AQP4-IgG antibody occurred in 59.8% and anti-MOG-IgG antibody in 11.5% of individuals. Antibody testing was lacking for 13.4% of patients. The estimated crude prevalence of NMOSD from Panama and the Dominican Republic was 1.62/100,000 (incidence of 0.08–0.41) and 0.73/100,000 (incidence 0.02–0.14), respectively. This multinational study contributes additional insights and data on the understanding of NMOSD in this Latin American region